Continued emphasis on elevating radiologists to senior executive leadership roles EL SEGUNDO, Calif.–(BUSINESS WIRE)–Radiology Partners (RP), the leading radiology practice in the U.S., announced today that Dr. Krishna Nallamshetty (@knallamMD) has been appointed to serve as the practice’s next Chief Medical Officer (CMO) effective immediately. As a member of RP’s senior leadership team Dr. Nallamshetty … [Read more…]
Uprise Health research provides new ways for benefits brokers to help HR teams boost nontraditional benefits to tackle burnout, work-life balance IRVINE, Calif.–(BUSINESS WIRE)–Uprise Health, a leading digital mental health company, today announced the findings of a new research study that details the overwhelming challenges human resources (HR) leaders are experiencing boosting nontraditional benefits like … [Read more…]
Partnership will utilize digital engagement strategies and research to create a robust clinical intervention that is meaningful and engaging to the target population LOS ANGELES–(BUSINESS WIRE)–mPulse Mobile, a leader in conversational AI and digital engagement solutions for the healthcare industry, today announced their collaboration with the Mount Sinai Health System, New York City’s largest academic … [Read more…]
WOBURN, Mass.–(BUSINESS WIRE)–Comera Life Sciences Holdings, Inc. (Nasdaq: CMRA), a life sciences company developing a new generation of bio-innovative biologic medicines to improve patient access, safety, and convenience, expanded its patent portfolio with the issuance of U.S. Patent No. 11,357,857 (the ‘857 patent), which provides Comera exclusive rights pertaining to certain excipients in its SQore™ … [Read more…]
– Extension study data suggest VIVJOA provides long-term reduction in the incidence of disease recurrence in RVVC patients – 85% of patients who took a 12-week course of VIVJOA completed 96 weeks without a recurrent VVC episode, with an average time of 92 weeks without recurrence DURHAM, N.C.–(BUSINESS WIRE)–Mycovia Pharmaceuticals, Inc. (“Mycovia”), an emerging biopharmaceutical … [Read more…]
PharmaEssentia was selected as one of the 2022 Industry Award Honorees, underscoring the significance of the introduction of BESREMi for the underserved MPN community BURLINGTON, Mass.–(BUSINESS WIRE)–PharmaEssentia USA Corporation, a subsidiary of PharmaEssentia Corporation (TPEx:6446), a global biopharmaceutical innovator based in Taiwan leveraging deep expertise and proven scientific principles to deliver new biologics in hematology … [Read more…]
The comprehensive solution aligns testing with clinical evidence, helping health plans better manage lab test utilization and spending EDEN PRAIRIE, Minn.–(BUSINESS WIRE)–Optum today announced the launch of a comprehensive laboratory benefit management solution designed to help health plans reduce unnecessary lab testing and ensure their members receive appropriate, high-quality tests. The potential savings for health … [Read more…]
SAN DIEGO–(BUSINESS WIRE)–MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced that Anne Frese, an experienced industry executive, joined MEI as chief people officer, a role reporting to Daniel P. Gold, chief executive officer. Ms. Frese will be responsible for the strategy and processes related to … [Read more…]
CAMBRIDGE, Mass.–(BUSINESS WIRE)–BioMed Realty, a leading provider of real estate solutions to the life science and technology industries, today announced that Takeda has leased the entire leading-edge research and development project totaling approximately 600,000 square feet in Kendall Square located at 585 Third Street in Cambridge, Massachusetts. The building is expected to be ready for … [Read more…]
VANCOUVER, British Columbia–(BUSINESS WIRE)–Alpha Cognition Inc. (TSX-V: ACOG) (OTCQB: ACOGF) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company committed to developing novel therapies for people with debilitating neurodegenerative disorders, today announced positive results from its pivotal bioequivalence study with ALPHA-1062, a proprietary, delayed release oral tablet formulation in development for the treatment of mild to … [Read more…]
